Marker Therapeutics (FRA:GX1) Other Current Payables : €0.33 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Marker Therapeutics Other Current Payables?

Marker Therapeutics's Other Current Payables for the quarter that ended in Mar. 2024 was €0.33 Mil.

Marker Therapeutics's quarterly Other Current Payables increased from Sep. 2023 (€0.35 Mil) to Dec. 2023 (€1.22 Mil) but then declined from Dec. 2023 (€1.22 Mil) to Mar. 2024 (€0.33 Mil).

Marker Therapeutics's annual Other Current Payables stayed the same from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.00 Mil) but then increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€1.22 Mil).

Marker Therapeutics Other Current Payables Historical Data

The historical data trend for Marker Therapeutics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marker Therapeutics Other Current Payables Chart

Marker Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Payables

Get a 7-Day Free Trial

1.22

Marker Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Current Payables	Get a 7-Day Free Trial															-	-	0.35	1.22	0.33

Marker Therapeutics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Marker Therapeutics Other Current Payables Related Terms

Thank you for viewing the detailed overview of Marker Therapeutics's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.

Marker Therapeutics (FRA:GX1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (FRA:GX1) » Definitions » Other Current Payables

Comparable Companies

Traded in Other Exchanges

MRKR:USA

Address

4551 Kennedy Commerce Drive, Houston, TX, USA, 77032

Website

http://www.markertherapeutics.com

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Marker Therapeutics (FRA:GX1) Headlines

No Headlines